Skip to Content


In the US, Toremifene (toremifene systemic) is a member of the following drug classes: hormones/antineoplastics, selective estrogen receptor modulators and is used to treat Breast Cancer and Breast Cancer - Metastatic.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Antineoplastic agent: Antiestrogen

Chemical Name


Foreign Names

  • Toremifenum (Latin)
  • Toremifen (German)
  • Torémifène (French)
  • Toremifeno (Spanish)

Generic Names

Brand Names

  • Fareston
    MSD, Thailand; Orion, Egypt; Orion, Georgia; Orion, Greece; Orion, Lebanon; Orion, Slovenia; Schering-Plough, South Africa; Baxter Oncology, Germany; CSP, France; Dong-A, South Korea; Merck Sharp & Dohme, Australia; Merck Sharp & Dohme, New Zealand; Nippon Kayaku, Japan; Orion, China; Orion, Czech Republic; Orion, United Kingdom; Orion, Ireland; Orion, Lithuania; Orion, Portugal; Orion, Romania; Orion Pharma, Finland; Orion Pharma, Sweden; Schering-Plough, Spain; Schering-Plough, Italy
  • Shu Rui
    Team, China
  • Toremifene
    Medisa Shinyaku, Japan

International Drug Name Search


BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.